117 related articles for article (PubMed ID: 38631685)
21. EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
Lindsay CR; Blackhall FH; Carmel A; Fernandez-Gutierrez F; Gazzaniga P; Groen HJM; Hiltermann TJN; Krebs MG; Loges S; López-López R; Muinelo-Romay L; Pantel K; Priest L; Riethdorf S; Rossi E; Terstappen L; Wikman H; Soria JC; Farace F; Renehan A; Dive C; Besse B; Michiels S
Eur J Cancer; 2019 Aug; 117():60-68. PubMed ID: 31254940
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal Change of Circulating Tumor Cells During Chemoradiation and Its Correlation with Prognosis in Advanced Nonsmall-Cell Lung Cancer Patients.
Liu J; Liu Y; Gu C; Zhang L; Lu X
Cancer Biother Radiopharm; 2023 Jun; 38(5):305-312. PubMed ID: 33481670
[No Abstract] [Full Text] [Related]
23. Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study.
Li Z; Xu K; Tartarone A; Santarpia M; Zhu Y; Jiang G
Transl Lung Cancer Res; 2021 Feb; 10(2):995-1006. PubMed ID: 33718038
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the Efficacy and Clinical Utility of Different Circulating Tumor Cell (CTC) Detection Assays in Patients with Chemotherapy-Naïve Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).
Papadaki MA; Messaritakis I; Fiste O; Souglakos J; Politaki E; Kotsakis A; Georgoulias V; Mavroudis D; Agelaki S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477700
[TBL] [Abstract][Full Text] [Related]
25. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer.
Shishido SN; Carlsson A; Nieva J; Bethel K; Hicks JB; Bazhenova L; Kuhn P
J Transl Med; 2019 Aug; 17(1):294. PubMed ID: 31462312
[TBL] [Abstract][Full Text] [Related]
26. Circulating tumor cells dynamics during chemotherapy predict survival and response in advanced non-small-cell lung cancer patients.
Wang Z; Zhang XC; Feng WN; Zhang L; Liu XQ; Guo WB; Deng YM; Zou QF; Yang JJ; Zhou Q; Wang BC; Chen HJ; Tu HY; Yan HH; Wu YL
Ther Adv Med Oncol; 2023; 15():17588359231167818. PubMed ID: 37113733
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.
Kulasinghe A; Kapeleris J; Kimberley R; Mattarollo SR; Thompson EW; Thiery JP; Kenny L; O'Byrne K; Punyadeera C
Cancer Med; 2018 Dec; 7(12):5910-5919. PubMed ID: 30565869
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
[TBL] [Abstract][Full Text] [Related]
29. Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer.
Xu Y; Ren X; Jiang T; Lv S; Gao K; Liu Y; Yan Y
BMC Cancer; 2023 May; 23(1):475. PubMed ID: 37226235
[TBL] [Abstract][Full Text] [Related]
30. Role of aneuploid circulating tumor cells and CD31
Zhang T; Zhang L; Gao Y; Wang Y; Liu Y; Zhang H; Wang Q; Hu F; Li J; Tan J; Wang DD; Gires O; Lin PP; Li B
Mol Oncol; 2021 Nov; 15(11):2891-2909. PubMed ID: 34455700
[TBL] [Abstract][Full Text] [Related]
31. CD44+ Circulating Tumor Endothelial Cells Indicate Poor Prognosis in Pancreatic Ductal Adenocarcinoma After Radical Surgery: A Pilot Study.
Xing C; Li Y; Ding C; Wang S; Zhang H; Chen L; Li P; Dai M
Cancer Manag Res; 2021; 13():4417-4431. PubMed ID: 34103996
[TBL] [Abstract][Full Text] [Related]
32. [The value of circulating tumor cells detected by chromosome centromere probe identification in diagnosis of non-small cell lung cancer].
Shen Q; Shen LS; Chen Q; Zhou JY; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):772-777. PubMed ID: 30347548
[No Abstract] [Full Text] [Related]
33. Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer.
Kapeleris J; Müller Bark J; Ranjit S; Irwin D; Hartel G; Warkiani ME; Leo P; O'Leary C; Ladwa R; O'Byrne K; Hughes BGM; Punyadeera C
Heliyon; 2022 Jul; 8(7):e09971. PubMed ID: 35874074
[TBL] [Abstract][Full Text] [Related]
34. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
Bian J; Yan K; Liu N; Xu X
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602
[TBL] [Abstract][Full Text] [Related]
35. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer.
Li J; Shi SB; Shi WL; Wang Y; Yu LC; Zhu LR; Ge LP
Transl Res; 2014 Jan; 163(1):27-35. PubMed ID: 24120632
[TBL] [Abstract][Full Text] [Related]
36. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
37. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection.
Bayarri-Lara C; Ortega FG; Cueto Ladrón de Guevara A; Puche JL; Ruiz Zafra J; de Miguel-Pérez D; Ramos AS; Giraldo-Ospina CF; Navajas Gómez JA; Delgado-Rodriguez M; Lorente JA; Serrano MJ
PLoS One; 2016; 11(2):e0148659. PubMed ID: 26913536
[TBL] [Abstract][Full Text] [Related]
38. Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response.
Sun WW; Xu ZH; Lian P; Gao BL; Hu JA
Onco Targets Ther; 2017; 10():2413-2424. PubMed ID: 28496340
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy.
Tong B; Xu Y; Zhao J; Chen M; Xing J; Zhong W; Wang M
Oncotarget; 2017 Oct; 8(49):86615-86624. PubMed ID: 29156821
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Punnoose EA; Atwal S; Liu W; Raja R; Fine BM; Hughes BG; Hicks RJ; Hampton GM; Amler LC; Pirzkall A; Lackner MR
Clin Cancer Res; 2012 Apr; 18(8):2391-401. PubMed ID: 22492982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
